Previous 10 | Next 10 |
2024-05-09 23:01:03 ET Cytosorbents Corporation (CTSO) Q1 2024 Earnings Conference Call May 9, 2024 16:30 ET Company Participants Eric Ribner - Investor Relations Phil Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kath...
2024-05-09 16:34:47 ET More on Cytosorbents CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cytosorbents Historical earnings data for Cytosorbents Financial information for Cytosorbents Read th...
Product Sales up a robust 14% over prior year, and a significant 22% sequentially We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Admi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that i...
PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial result...
PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced ...
2024-03-14 22:24:03 ET CytoSorbents Corporation (CTSO) Q4 2023 Earnings Conference Call March 14, 2024 04:30 PM ET Company Participants Eric Ribner - Moderator Phillip P. Chan - Chief Executive Officer Kathleen Bloch - Chief Financial Officer Efthymios N. Del...
2024-03-14 17:09:01 ET More on Cytosorbents Dawson James sees Cytosorbents' Cytosorb as approvable, but raises risk CytoSorbents drops as blood purification system fails key trial Seeking Alpha’s Quant Rating on Cytosorbents Historical earnings data fo...
STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year ...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on...
PRINCETON, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the reg...